Neuphoria Therapeutics Inc. Common Stock (NEUP)

• Market cap: $8.56M
• 1 day: -1.62%
• 5 days: -11.78%
• 1 month: 5.87%
• 3 months: 1,407.27%
• 6 months: 639.34%
• Year to date: 66.21%
• 1 year: 342.73%
• 5 years: -66.94%
• 10 years: -66.94%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Employees: 24

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

0.11% less ownership

Funds ownership: 0.12% [Q3] → 0% (-0.11%) [Q4]

11% less funds holding

Funds holding: 9 [Q3] → 8 (-1) [Q4]

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

75% less capital invested

Capital invested by funds: $1.1M [Q3] → $273K (-$826K) [Q4]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $21 331% upside
• Avg. target: $21 331% upside
• High target: $21 331% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 18% 1-year accuracy 75 / 411 met price target

331% upside $21

Buy Maintained

4 Feb 2025